Skip to main content

Articles

Page 12 of 108

  1. Breast cancer is the most common malignancy to spread to the orbit and periorbit, and the invasive lobular carcinoma (ILC) histologic subtype of breast cancer has been reported to form these ophthalmic metasta...

    Authors: Martin Blohmer, Li Zhu, Jennifer M. Atkinson, Sushil Beriwal, Joshua L. Rodríguez-López, Margaret Rosenzweig, Adam M. Brufsky, George Tseng, Peter C. Lucas, Adrian V. Lee, Steffi Oesterreich and Rachel C. Jankowitz
    Citation: Breast Cancer Research 2020 22:70
  2. In the evaluation of PD-L1 expression to select patients for anti-PD-1/PD-L1 treatment, uniform guidelines that account for different immunohistochemistry assays, different cell types and different cutoff valu...

    Authors: Hua Guo, Qingqing Ding, Yun Gong, Michael Z. Gilcrease, Min Zhao, Jun Zhao, Dawen Sui, Yun Wu, Hui Chen, Hui Liu, Jinxia Zhang, Erika Resetkova, Stacy L. Moulder, Wei-Lien Wang and Lei Huo
    Citation: Breast Cancer Research 2020 22:69
  3. Breast cancer is a highly heterogeneous disease characterized by multiple histologic and molecular subtypes. While a myriad of breast cancer cell lines have been developed over the past 60 years, estrogen rece...

    Authors: Jessica Finlay-Schultz, Britta M. Jacobsen, Duncan Riley, Kiran V. Paul, Scott Turner, Andrea Ferreira-Gonzalez, J. Chuck Harrell, Peter Kabos and Carol A. Sartorius
    Citation: Breast Cancer Research 2020 22:68
  4. Obesity induces molecular changes that may favor tumor progression and metastatic spread, leading to impaired survival outcomes in breast cancer. Adenylate cyclase-associated protein 1 (CAP1), an actin regulat...

    Authors: Malin Bergqvist, Karin Elebro, Malte Sandsveden, Signe Borgquist and Ann H. Rosendahl
    Citation: Breast Cancer Research 2020 22:67
  5. Triple-negative breast cancer (TNBC) is characterized by high rates of recurrence and poor overall survival. This is due, in part, to a deficiency of targeted therapies, making it essential to identify therape...

    Authors: Melyssa S. Roberts, Lindsey J. Anstine, Viviane S. Finke, Benjamin L. Bryson, Bryan M. Webb, Kristen L. Weber-Bonk, Darcie D. Seachrist, Parth R. Majmudar and Ruth A. Keri
    Citation: Breast Cancer Research 2020 22:66
  6. Crown-like structures in breast adipose tissue (CLS-B), composed of necrotic adipocytes encircled by macrophages, are associated with obesity and hypothesized to worsen breast cancer prognosis; however, data a...

    Authors: Maret L. Maliniak, Aswathy Miriam Cheriyan, Mark E. Sherman, Yuan Liu, Keerthi Gogineni, Jiaqi Liu, Jiabei He, Uma Krishnamurti, Jasmine Miller-Kleinhenz, Ryan Ashiqueali, Jinjing He, Rami Yacoub and Lauren E. McCullough
    Citation: Breast Cancer Research 2020 22:65
  7. Aging is a comorbidity of breast cancer suggesting that aging-associated transcriptome changes may promote breast cancer progression. However, the mechanism underlying the age effect on breast cancer remains p...

    Authors: Xiang Gu, Bingzhi Wang, Haiyan Zhu, You Zhou, Aaron M. Horning, Tim H-M Huang, Yidong Chen, Peter Houghton, Zhao Lai, Joel E. Michalek and Lu-Zhe Sun
    Citation: Breast Cancer Research 2020 22:64
  8. Basal-like breast cancer (BLBC) is a poorly characterised, heterogeneous disease. Patients are diagnosed with aggressive, high-grade tumours and often relapse with chemotherapy resistance. Detailed understandi...

    Authors: Laura A. Baker, Holly Holliday, Daniel Roden, Christoph Krisp, Sunny Z. Wu, Simon Junankar, Aurelien A. Serandour, Hisham Mohammed, Radhika Nair, Geetha Sankaranarayanan, Andrew M. K. Law, Andrea McFarland, Peter T. Simpson, Sunil Lakhani, Eoin Dodson, Christina Selinger…
    Citation: Breast Cancer Research 2020 22:63
  9. African American/Black women with breast cancer have poorer survival than White women, and this disparity persists even after adjusting for non-biological factors. Differences in tumor immune biology have been...

    Authors: Yara Abdou, Kristopher Attwood, Ting-Yuan David Cheng, Song Yao, Elisa V. Bandera, Gary R. Zirpoli, Rochelle Payne Ondracek, Leighton Stein, Wiam Bshara, Thaer Khoury, Christine B. Ambrosone and Angela R. Omilian
    Citation: Breast Cancer Research 2020 22:62
  10. Mitochondrial dynamics underlies malignant transformation, cancer progression, and response to treatment. Current research presents conflicting evidence for functions of mitochondrial fission and fusion in tum...

    Authors: Brock A. Humphries, Alyssa C. Cutter, Johanna M. Buschhaus, Yu-Chih Chen, Tonela Qyli, Dilrukshika S. W. Palagama, Samantha Eckley, Tanner H. Robison, Avinash Bevoor, Benjamin Chiang, Henry R. Haley, Saswat Sahoo, Phillip C. Spinosa, Dylan B. Neale, Jagadish Boppisetti, Debashis Sahoo…
    Citation: Breast Cancer Research 2020 22:60
  11. Breast cancer is a heterogeneous disease. Hence, stratification of patients based on the subtype of breast cancer is key to its successful treatment. Among all the breast cancer subtypes, basal-like breast can...

    Authors: Ritama Paul, Ming Luo, Xueying Mo, Jason Lu, Syn Kok Yeo and Jun-Lin Guan
    Citation: Breast Cancer Research 2020 22:59

    The Correction to this article has been published in Breast Cancer Research 2020 22:71

  12. Ultrafast dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI)-derived kinetic parameters have demonstrated at least equivalent accuracy to standard DCE-MRI in differentiating malignant from benign b...

    Authors: Natsuko Onishi, Meredith Sadinski, Mary C. Hughes, Eun Sook Ko, Peter Gibbs, Katherine M. Gallagher, Maggie M. Fung, Theodore J. Hunt, Danny F. Martinez, Amita Shukla-Dave, Elizabeth A. Morris and Elizabeth J. Sutton
    Citation: Breast Cancer Research 2020 22:58
  13. For breast cancer patients undergoing neoadjuvant chemotherapy (NAC), pathologic complete response (pCR; no invasive or in situ) cannot be assessed non-invasively so all patients undergo surgery. The aim of ou...

    Authors: Elizabeth J. Sutton, Natsuko Onishi, Duc A. Fehr, Brittany Z. Dashevsky, Meredith Sadinski, Katja Pinker, Danny F. Martinez, Edi Brogi, Lior Braunstein, Pedram Razavi, Mahmoud El-Tamer, Virgilio Sacchini, Joseph O. Deasy, Elizabeth A. Morris and Harini Veeraraghavan
    Citation: Breast Cancer Research 2020 22:57
  14. Endocrine therapy is recommended as a first-line treatment for hormone receptor-positive metastatic breast cancer (HR+MBC) patients. No biomarker has been validated to predict tumor progression in that setting...

    Authors: Florian Clatot, Anne Perdrix, Ludivine Beaussire, Justine Lequesne, Christelle Lévy, George Emile, Michael Bubenheim, Sigrid Lacaille, Céline Calbrix, Laetitia Augusto, Cécile Guillemet, Cristina Alexandru, Maxime Fontanilles, David Sefrioui, Lucie Burel, Sabine Guénot…
    Citation: Breast Cancer Research 2020 22:56
  15. Cancer patients have been reported to be at higher risk of COVID-19 complications and deaths. We report the characteristics and outcome of patients diagnosed with COVID-19 during breast cancer treatment at Ins...

    Authors: Perrine Vuagnat, Maxime Frelaut, Toulsie Ramtohul, Clémence Basse, Sarah Diakite, Aurélien Noret, Audrey Bellesoeur, Vincent Servois, Delphine Hequet, Enora Laas, Youlia Kirova, Luc Cabel, Jean-Yves Pierga, Laurence Bozec, Xavier Paoletti, Paul Cottu…
    Citation: Breast Cancer Research 2020 22:55
  16. Neoadjuvant endocrine therapy (NET) has demonstrated efficacy in post-menopausal patients with hormone-responsive breast cancer. This trial was designed to compare the efficacy of neoadjuvant chemotherapy (NCT...

    Authors: Hee Jeong Kim, Woo Chul Noh, Eun Sook Lee, Yong Sik Jung, Lee Su Kim, Wonshik Han, Seok Jin Nam, Gyung -Yub Gong, Hwa Jung Kim and Sei Hyun Ahn
    Citation: Breast Cancer Research 2020 22:54
  17. The incidence of ductal carcinoma in situ (DCIS) has increased substantially since the introduction of mammography screening. Nevertheless, little is known about the natural history of preclinical DCIS in the ...

    Authors: Sarocha Chootipongchaivat, Nicolien T. van Ravesteyn, Xiaoxue Li, Hui Huang, Harald Weedon-Fekjær, Marc D. Ryser, Donald L. Weaver, Elizabeth S. Burnside, Brandy M. Heckman-Stoddard, Harry J. de Koning and Sandra J. Lee
    Citation: Breast Cancer Research 2020 22:53
  18. An amendment to this paper has been published and can be accessed via the original article.

    Authors: Lori J. Goldstein, Raymond P. Perez, Denise Yardley, Linda K. Han, James M. Reuben, Hui Gao, Susan McCanna, Beth Butler, Pier Adelchi Ruffini, Yi Liu, Roberto R. Rosato and Jenny C. Chang
    Citation: Breast Cancer Research 2020 22:52

    The original article was published in Breast Cancer Research 2020 22:4

  19. The tamoxifen metabolite, Z-endoxifen, demonstrated promising antitumor activity in endocrine-resistant estrogen receptor-positive (ER+) breast cancer. We compared the antitumor activity of Z-endoxifen with ta...

    Authors: Swaathi Jayaraman, Xiaonan Hou, Mary J. Kuffel, Vera J. Suman, Tanya L. Hoskin, Kathryn E. Reinicke, David G. Monroe, Krishna R. Kalari, Xiaojia Tang, Megan A. Zeldenrust, Jingfei Cheng, Elizabeth S. Bruinsma, Sarah A. Buhrow, Renee M. McGovern, Stephanie L. Safgren, Chad A. Walden…
    Citation: Breast Cancer Research 2020 22:51
  20. Alterations in estrogen and progesterone signaling, via their respective receptors, estrogen receptor alpha (ERα) and progesterone receptor (PR), respectively, are largely involved in the development of breast...

    Authors: Henri-Philippe Konan, Loay Kassem, Soleilmane Omarjee, Ausra Surmieliova-Garnès, Julien Jacquemetton, Elodie Cascales, Amélie Rezza, Olivier Trédan, Isabelle Treilleux, Coralie Poulard and Muriel Le Romancer
    Citation: Breast Cancer Research 2020 22:50
  21. Most breast cancer-associated fibroblasts (CAFs) are active and important cancer-promoting cells, with significant impact on patient prognosis. Therefore, we investigated here the role of the protein kinase AT...

    Authors: Mysoon M. Al-Ansari, Maher Al-Saif, Maria Arafah, Abdelmonneim M. Eldali, Asma Tulbah, Taher Al-Tweigeri, Abdelhabib Semlali, Khalid S. Khabar and Abdelilah Aboussekhra
    Citation: Breast Cancer Research 2020 22:49
  22. The human epidermal growth factor receptor (HER) family, notably EGFR, is overexpressed in most triple-negative breast cancer (TNBC) cases and provides cancer cells with compensatory signals that greatly contr...

    Authors: Tejaswini P. Reddy, Dong S. Choi, Ann C. Anselme, Wei Qian, Wen Chen, Johan Lantto, Ivan D. Horak, Michael Kragh, Jenny C. Chang and Roberto R. Rosato
    Citation: Breast Cancer Research 2020 22:48
  23. The presence of tumor-infiltrating lymphocytes has been associated with prognosis and chemotherapy response, particularly in high-risk breast cancer subtypes. There is limited data so far as to (i) how tumor-i...

    Authors: Cornelia Kolberg-Liedtke, Oleg Gluz, Fred Heinisch, Friedrich Feuerhake, Hans Kreipe, Michael Clemens, Benno Nuding, Wolfram Malter, Toralf Reimer, Rachel Wuerstlein, Monika Graeser, Steve Shak, Ulrike Nitz, Ronald Kates, Matthias Christgen and Nadia Harbeck
    Citation: Breast Cancer Research 2020 22:47
  24. The presence of tumour-infiltrating lymphocytes (TILs) is associated with response to neoadjuvant chemotherapy among patients with triple-negative and HER2-positive breast cancer. However, the significance of ...

    Authors: Signe Korsgaard Skriver, Maj-Britt Jensen, Ann Soegaard Knoop, Bent Ejlertsen and Anne-Vibeke Laenkholm
    Citation: Breast Cancer Research 2020 22:46
  25. The therascreen PIK3CA mutation assay and the alpha-specific PI3K inhibitor alpelisib are FDA-approved for identifying and treating patients with advanced PIK3CA-mutated (PIK3CAmut) breast cancer (BC). However, i...

    Authors: Olga Martínez-Sáez, Nuria Chic, Tomás Pascual, Barbara Adamo, Maria Vidal, Blanca González-Farré, Esther Sanfeliu, Francesco Schettini, Benedetta Conte, Fara Brasó-Maristany, Adela Rodríguez, Débora Martínez, Patricia Galván, Ana Belén Rodríguez, Antonio Martinez, Montserrat Muñoz…
    Citation: Breast Cancer Research 2020 22:45
  26. Racial disparities in breast cancer survival between Black and White women persist across all stages of breast cancer. The metabolic syndrome (MetS) of insulin resistance disproportionately affects more Black ...

    Authors: Emily J. Gallagher, Kezhen Fei, Sheldon M. Feldman, Elisa Port, Neil B. Friedman, Susan K. Boolbol, Brigid Killelea, Melissa Pilewskie, Lydia Choi, Tari King, Anupma Nayak, Rebeca Franco, Daliz Cruz, Irini M. Antoniou, Derek LeRoith and Nina A. Bickell
    Citation: Breast Cancer Research 2020 22:40
  27. Early life environmental exposures affect breast development and breast cancer risk in adulthood. The breast is particularly vulnerable during puberty when mammary epithelial cells proliferate exponentially. I...

    Authors: Adam Burkholder, Dennis Akrobetu, Arun R. Pandiri, Kiki Ton, Sue Kim, Brian I. Labow, Laura C. Nuzzi, Joseph M. Firriolo, Sallie S. Schneider, Suzanne E. Fenton and Natalie D. Shaw
    Citation: Breast Cancer Research 2020 22:44
  28. Next-generation sequencing of Sri Lankan families with inherited cancer syndromes resulted in the identification of five BRCA2 variants of unknown clinical significance. Interpreting such variants poses significa...

    Authors: Nirmala Sirisena, Kajal Biswas, Teresa Sullivan, Stacey Stauffer, Linda Cleveland, Eileen Southon, Vajira H. W. Dissanayake and Shyam K. Sharan
    Citation: Breast Cancer Research 2020 22:43
  29. Stromal and collagen biology has a significant impact on tumorigenesis and metastasis. Collagen is a major structural extracellular matrix component in breast cancer, but its role in cancer progression is the ...

    Authors: Laurent Gole, Joe Yeong, Jeffrey Chun Tatt Lim, Kok Haur Ong, Hao Han, Aye Aye Thike, Yong Cheng Poh, Sidney Yee, Jabed Iqbal, Wanjin Hong, Bernett Lee, Weimiao Yu and Puay Hoon Tan
    Citation: Breast Cancer Research 2020 22:42
  30. In utero endocrine disruption is linked to increased risk of breast cancer later in life. Despite numerous studies establishing this linkage, the long-term molecular changes that predispose mammary cells to ca...

    Authors: Clarissa Wormsbaecher, Andrea R. Hindman, Alex Avendano, Marcos Cortes-Medina, Caitlin E. Jones, Andrew Bushman, Lotanna Onua, Claire E. Kovalchin, Alina R. Murphy, Hannah L. Helber, Ali Shapiro, Kyle Voytovitch, Xingyan Kuang, Renan Aguilar-Valenzuela, Jennifer L. Leight, Jonathan W. Song…
    Citation: Breast Cancer Research 2020 22:41
  31. Altered signaling pathways typify breast cancer and serve as direct inputs to steroid hormone receptor sensors. We previously reported that phospho-Ser134-GR (pS134-GR) species are elevated in triple-negative bre...

    Authors: Carlos Perez Kerkvliet, Amy R. Dwyer, Caroline H. Diep, Robert H. Oakley, Christopher Liddle, John A. Cidlowski and Carol A. Lange
    Citation: Breast Cancer Research 2020 22:39
  32. The highest incidence of breast cancer is in the Western world. Several aspects of the Western lifestyle are known risk factors for breast cancer. In particular, previous studies have shown that cholesterol le...

    Authors: Céline Ben Hassen, Jorge L. Gutierrez-Pajares, Cyrille Guimaraes, Roseline Guibon, Michelle Pinault, Gaëlle Fromont and Philippe G. Frank
    Citation: Breast Cancer Research 2020 22:38
  33. At least 50% of triple negative breast cancer (TNBC) overexpress the epidermal growth factor receptor, EGFR, which paved the way for clinical trials investigating its blockade. Outcomes remained dismal stemmin...

    Authors: Brooke N. McKnight, Seongho Kim, Julie L. Boerner and Nerissa T. Viola
    Citation: Breast Cancer Research 2020 22:37
  34. Multigene panels are routinely used to assess for predisposing germline mutations in families at high breast cancer risk. The number of variants of unknown significance thereby identified increases with the nu...

    Authors: Cédric Van Marcke, Raphaël Helaers, Anne De Leener, Ahmad Merhi, Céline A. Schoonjans, Jérôme Ambroise, Christine Galant, Paul Delrée, Françoise Rothé, Isabelle Bar, Elsa Khoury, Pascal Brouillard, Jean-Luc Canon, Peter Vuylsteke, Jean-Pascal Machiels, Martine Berlière…
    Citation: Breast Cancer Research 2020 22:36
  35. Osteoclast activation is a hallmark of breast cancer-induced bone disease while little is known about the role of osteoblasts in this process. Recently, we identified the homeodomain protein TG-interacting fac...

    Authors: Marie-Therese Haider, Hiroaki Saito, Jennifer Zarrer, Kevin Uzhunnumpuram, Sankari Nagarajan, Vijayalakshmi Kari, Michael Horn-Glander, Stefan Werner, Eric Hesse and Hanna Taipaleenmäki
    Citation: Breast Cancer Research 2020 22:34
  36. The PI3K/AKT/mTORC1 axis is implicated in hormone receptor-positive HER2-negative metastatic breast cancer (HR+ HER2− mBC) resistance to anti-estrogen treatments. Based on results of the BOLERO-2 trial, the mT...

    Authors: Claudio Vernieri, Francesca Corti, Federico Nichetti, Francesca Ligorio, Sara Manglaviti, Emma Zattarin, Carmen G. Rea, Giuseppe Capri, Giulia V. Bianchi and Filippo de Braud
    Citation: Breast Cancer Research 2020 22:33
  37. The immune microenvironment in ductal carcinoma in situ (DCIS) and its significance are not well established. This study was conducted to evaluate the immune microenvironment of DCIS including the composition ...

    Authors: Milim Kim, Yul Ri Chung, Hyun Jeong Kim, Ji Won Woo, Soomin Ahn and So Yeon Park
    Citation: Breast Cancer Research 2020 22:32
  38. After publication of the original article [1], we were notified that the wrong version of Fig. 2b has been published

    Authors: Pankaj Chaudhary, Lee D. Gibbs, Sayantan Maji, Cheryl M. Lewis, Sumihiro Suzuki and Jamboor K. Vishwanatha
    Citation: Breast Cancer Research 2020 22:31

    The original article was published in Breast Cancer Research 2020 22:11

  39. Breast cancer is rare in men, but management is focused on tumor characteristics commonly found in female breast cancer. The tumor microenvironment of male breast cancer is less well understood, and insight ma...

    Authors: Si-Qi Qiu, Johan van Rooijen, Hilde H. Nienhuis, Bert van der Vegt, Hetty Timmer-Bosscha, Elise van Leeuwen-Stok, Annemiek M. E. Walenkamp, Carolien H. M. van Deurzen, Geertruida H. de Bock, Elisabeth G. E. de Vries and Carolien P. Schröder
    Citation: Breast Cancer Research 2020 22:30
  40. Breast cancer patients with early-stage disease are increasingly administered neoadjuvant chemotherapy (NAC) to downstage their tumors prior to surgery. In this setting, approximately 31% of patients fail to r...

    Authors: Anup Tank, Hannah M. Peterson, Vivian Pera, Syeda Tabassum, Anais Leproux, Thomas O’Sullivan, Eric Jones, Howard Cabral, Naomi Ko, Rita S. Mehta, Bruce J. Tromberg and Darren Roblyer
    Citation: Breast Cancer Research 2020 22:29
  41. After the publication of the original article [1], we were notified the upper panel of the Fig. 1, where the patients’ codes are listed, was cropped by mistake so the patients 1–8 are repeated.

    Authors: Adi Zundelevich, Maya Dadiani, Smadar Kahana-Edwin, Amit Itay, Tal Sella, Moran Gadot, Karen Cesarkas, Sarit Farage-Barhom, Efrat Glick Saar, Eran Eyal, Nitzan Kol, Anya Pavlovski, Nora Balint-Lahat, Daniela Dick-Necula, Iris Barshack, Bella Kaufman…
    Citation: Breast Cancer Research 2020 22:28

    The original article was published in Breast Cancer Research 2020 22:16

  42. Palbociclib improves outcomes for women with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (HR+/HER2− ABC). Dose reductions are recommended for the manageme...

    Authors: Johannes Ettl, Seock-Ah Im, Jungsil Ro, Norikazu Masuda, Marco Colleoni, Patrick Schnell, Eustratios Bananis, Dongrui R. Lu, Massimo Cristofanilli, Hope S. Rugo and Richard S. Finn
    Citation: Breast Cancer Research 2020 22:27
  43. Breast cancer stem cells (BCSCs) are typically seed cells of breast tumor that initiate and maintain tumor growth. MiR-7, as a cancer inhibitor, decreases the BCSC subset and inhibits tumor progression through...

    Authors: Miao Li, Meng Pan, Chengzhong You, Fengshu Zhao, Di Wu, Mei Guo, Hui Xu, Fangfang Shi, Danfeng Zheng and Jun Dou
    Citation: Breast Cancer Research 2020 22:26
  44. After publication of the original article [1], we were notified that columns in Table 2 were erroneously displayed.

    Authors: Nasim Mavaddat, Antonis C. Antoniou, Thea M. Mooij, Maartje J. Hooning, Bernadette A. Heemskerk-Gerritsen, Catherine Noguès, Marion Gauthier-Villars, Olivier Caron, Paul Gesta, Pascal Pujol, Alain Lortholary, Daniel Barrowdale, Debra Frost, D. Gareth Evans, Louise Izatt, Julian Adlard…
    Citation: Breast Cancer Research 2020 22:25

    The original article was published in Breast Cancer Research 2020 22:8

  45. Experimental and epidemiological studies demonstrate a role for 27-hydroxycholesterol (27HC) in breast cancer development, though results are conflicting. Cholesterol 27-hydroxylase (CYP27A1) and oxysterol 7-a...

    Authors: Charlotte Le Cornet, Britta Walter, Disorn Sookthai, Theron S. Johnson, Tilman Kühn, Ester Herpel, Rudolf Kaaks and Renée T. Fortner
    Citation: Breast Cancer Research 2020 22:23
  46. In preclinical studies, the expression of vascular endothelial growth factor (VEGF) in hormone receptor-positive breast cancer is associated with estrogen-independent tumor growth and resistance to endocrine t...

    Authors: Christos Vaklavas, Brian S. Roberts, Katherine E. Varley, Nancy U. Lin, Minetta C. Liu, Hope S. Rugo, Shannon Puhalla, Rita Nanda, Anna Maria Storniolo, Lisa A. Carey, Mansoor N. Saleh, Yufeng Li, Jennifer F. Delossantos, William E. Grizzle, Albert F. LoBuglio, Richard M. Myers…
    Citation: Breast Cancer Research 2020 22:22
  47. Polygenic factors are estimated to account for an additional 18% of the familial relative risk of breast cancer, with those at the highest level of polygenic risk distribution having a least a twofold increase...

    Authors: Tatiane Yanes, Mary-Anne Young, Bettina Meiser and Paul A. James
    Citation: Breast Cancer Research 2020 22:21

Annual Journal Metrics

  • 2022 Citation Impact
    7.4 - 2-year Impact Factor
    7.4 - 5-year Impact Factor
    1.764 - SNIP (Source Normalized Impact per Paper)
    2.408 - SJR (SCImago Journal Rank)

    2023 Speed
    20 days submission to first editorial decision for all manuscripts (Median)
    129 days submission to accept (Median)

    2023 Usage 
    2,432,781 downloads
    1,561 Altmetric mentions